Sofosbuvir and velpatasvir

Generic Name: Sofosbuvir and velpatasvir

Indication: 1.用于治疗基因1～6型、混合型及未知型慢性丙型肝炎病毒(HCV) 的成人感染患者。

2.美国FDA批准用于治疗6岁及以上或体重超过17千克的6种基因型（GT-1,-2,-3,-4,-5,-6）的HCV儿童感染者（无肝硬化或轻度肝硬化）。

Clinical Trials

Trial for the Treatment of Acute Hepatitis C for 8 Weeks With Sofosbuvir/Velpatasvir

Phase 2

Completed

Conditions: Hepatitis C
Acute Hepatitis C

Interventions: Drug: Sofosbuvir and Velpatasvir

First Posted Date: 2019-01-28

Last Posted Date: 2021-07-06

Lead Sponsor: Hannover Medical School

Target Recruit Count: 20

Registration Number: NCT03818308

Locations: 🇩🇪
Allgemeinmedizinische und internistische Praxis, Berlin-Friedrichshain, Germany
🇩🇪
Zentrum für Infektiologie Prenzlauer Berg, Berlin, Germany
🇩🇪
Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik I, Bonn, Germany

and more 11 locations

The Use of Hepatitis C Positive Livers in Hepatitis C Negative Liver Transplant Recipients

Phase 2

Active, not recruiting

Conditions: Liver Transplant
Hepatitis C

Interventions: Drug: sofosbuvir/velpatasvir

First Posted Date: 2019-01-28

Last Posted Date: 2024-10-18

Lead Sponsor: Naudia Jonassaint. MD

Target Recruit Count: 73

Registration Number: NCT03819322

Locations: 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States

The Use of Hepatitis C Positive Kidneys in Hepatitis C Negative Kidney Transplant Recipients

Phase 2

Active, not recruiting

Conditions: Kidney Transplantation
Hepatitis C

Interventions: Drug: sofosbuvir/velpatasvir

First Posted Date: 2019-01-18

Last Posted Date: 2024-08-23

Lead Sponsor: Amit D Tevar, MD

Target Recruit Count: 30

Registration Number: NCT03809533

Locations: 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States

Transplanting Hepatitis C Lungs Into Negative Lung Recipients

Phase 1

Completed

Conditions: Lung Diseases

Interventions: Drug: Zepatier
Drug: Epclusa

First Posted Date: 2018-10-30

Last Posted Date: 2023-04-14

Lead Sponsor: University of Pennsylvania

Target Recruit Count: 10

Registration Number: NCT03724149

Locations: 🇺🇸
Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

Prevention of De Novo HCV With Antiviral HCV Therapy Post-Liver and Post-Kidney Transplant

Phase 4

Completed

Conditions: Hepatitis C
Transplantation Disease Transmission

Interventions: Drug: Sofosbuvir/Velpatasvir
Drug: Sofosbuvir/Velpatasvir/Voxilaprevir

First Posted Date: 2018-08-08

Last Posted Date: 2021-03-03

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 122

Registration Number: NCT03619837

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States
🇺🇸
Baylor University Medical Center - Dallas, Dallas, Texas, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

and more 3 locations

Switch to Genvoya Followed by HCV Therapy With Epclusa Followed by Simplification of HIV Therapy With Biktarvy in Patients With HIV-HCV Co-Infected Subjects on Opioid Substitution Therapy

Phase 4

Conditions: Hepatitis C, Chronic
Co-infection
Buprenorphine Dependence
HCV Coinfection
Methadone Dependence
Opioid Dependence
Bone Diseases, Metabolic
HIV-1-infection
HIV/AIDS

Interventions: Drug: Genvoya
Drug: Epclusa
Drug: Biktarvy

First Posted Date: 2018-06-08

Last Posted Date: 2019-12-24

Lead Sponsor: Saskatchewan Health Authority - Regina Area

Target Recruit Count: 25

Registration Number: NCT03549312

Locations: 🇨🇦
Saskatchewan Health Authority, Regina, Saskatchewan, Canada

People With CHC Who Achieved a Sustained Virological Response Following Therapy With Direct Acting Antiviral Agents

Phase 4

Active, not recruiting

Conditions: Cardiovascular Diseases
Hepatitis C, Chronic
Diabetes Mellitus

Interventions: Drug: Epclusa

First Posted Date: 2018-05-11

Last Posted Date: 2025-05-16

Lead Sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Target Recruit Count: 121

Registration Number: NCT03520660

Locations: 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States

A TEst and Treat Intervention aMong Current People Who Inject Drugs With HCV Attending Needle and Syringe PrOgrams

Not Applicable

Completed

Conditions: Hepatitis C

Interventions: Device: HCV RNA Point of Care
Drug: Sofosbuvir/velpatasvir
Drug: Glecaprevir/pibrentasvir

First Posted Date: 2018-04-10

Last Posted Date: 2023-01-17

Lead Sponsor: Kirby Institute

Target Recruit Count: 101

Registration Number: NCT03492112

Locations: 🇦🇺
NUAA NSP, Sydney, New South Wales, Australia

Transplant of Redeemed Organs by Judicious Administration of New Direct-Acting Antivirals for Hepatitis-C Heart Recipients

Phase 2

Conditions: Heart Failure

Interventions: Drug: Epclusa

First Posted Date: 2017-12-26

Last Posted Date: 2023-01-26

Lead Sponsor: Baylor Research Institute

Target Recruit Count: 15

Registration Number: NCT03383419

Locations: 🇺🇸
Baylor University Medical Center, Dallas, Texas, United States
🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Duke University Medical Center, Durham, North Carolina, United States

Expanding the Pool in Lung Transplantation

Phase 1

Completed

Conditions: Lung Transplant
Hepatitis C

Interventions: Drug: Epclusa

First Posted Date: 2017-12-19

Last Posted Date: 2022-12-16

Lead Sponsor: Pablo Sanchez

Target Recruit Count: 10

Registration Number: NCT03377478

Locations: 🇺🇸
UPMC, Pittsburgh, Pennsylvania, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy